We present a case of a pregnant woman at 27 weeks of gestation with systemic lupus erythematosus who developed severe thrombocytopenia presenting with melena, epistaxis, gum bleeding and frank hematuria. She was resistant to most treatment modalities, including steroids, intravenous immunoglobulins (IVIG), rituximab, IV cyclophosphamide and eltrombopag. She responded to romiplostim with normalization of her platelet count, which enabled her to be delivered safely at 34 weeks of gestation.
WallaceDJ. The clinical presentation of systemic lupus erythematosus. In: WallaceDJHanBH (eds). Dubois’ lupus erythematosus , Baltimore, MD: Williams & Wilkins, 1997; 627–633.
2.
MeyersB. Diagnosis and management of maternal thrombocytopenia in pregnancy. Br J Haematol2012; 158: 3–15.
3.
CrowtherMABurrowsRFGinsbergJ. Thrombocytopenia in pregnancy: Diagnosis, pathogenesis and management. Blood Rev1996; 10: 8–16.
4.
LouwesHZeinali LathoriOAVellengaE. Platelet kinetic studies in patients with idiopathic thrombocytopenic purpura. Am J Med1999; 106: 430–434.
5.
StasiREvangelistaMLAmadoriS. Novel thrombopoietic agents. A review of their use in idiopathic thrombocytopenic purpura. Drugs2008; 68: 901–912.
6.
KuwanaKKaburakiJOkazakiY. Two types of autoantibody-mediated thrombocytopenia in patients with systemic lupus erythematosus. Rheumatology (Oxford)2006; 45: 851–854.
7.
HomeidaSEbdonCBattyP. New thrombopoietin receptor agonists for platelet disorders. Drugs Today (Barc)2012; 48: 293–301.
8.
RiceL. Treatment of immune thrombocytopenic purpura: focus on eltrombopag. Biologics2009; 3: 151–157.
9.
KhellafMMichelMQuittetP. Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program. Blood2011; 118: 4338–4345.
10.
Gonzalez-NietoJAMartin-SuarezIQuattrinoS. The efficacy of romiplostim in the treatment of severe thrombocytopenia associated to Evans syndrome refractory to rituximab. Lupus2011; 20: 1321–1323.
